Who Generates More Revenue? Corcept Therapeutics Incorporated or Arrowhead Pharmaceuticals, Inc.

Biotech Revenue Showdown: Corcept vs. Arrowhead

__timestampArrowhead Pharmaceuticals, Inc.Corcept Therapeutics Incorporated
Wednesday, January 1, 201417500026551000
Thursday, January 1, 201538200050286000
Friday, January 1, 201615833381321000
Sunday, January 1, 201731407709159201000
Monday, January 1, 201816142321251247000
Tuesday, January 1, 2019168795577306486000
Wednesday, January 1, 202087992066353874000
Friday, January 1, 2021138287000365978000
Saturday, January 1, 2022243231000401858000
Sunday, January 1, 2023240735000482375000
Monday, January 1, 20243551000
Loading chart...

Infusing magic into the data realm

Revenue Race: Corcept vs. Arrowhead

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Corcept Therapeutics Incorporated has consistently outperformed Arrowhead Pharmaceuticals, Inc. in terms of revenue. From 2014 to 2023, Corcept's revenue surged by approximately 1,700%, peaking at nearly $482 million in 2023. In contrast, Arrowhead's revenue, while growing, reached a high of around $243 million in 2022, marking a significant increase from its modest beginnings in 2014.

Corcept's strategic focus on developing treatments for metabolic and oncologic disorders has paid off, as evidenced by its steady revenue growth. Meanwhile, Arrowhead, known for its RNA interference therapies, has shown promising revenue trends, particularly in recent years. However, the data for 2024 is incomplete, leaving room for speculation on future performance. As these companies continue to innovate, the revenue race remains a fascinating aspect of their ongoing rivalry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025